ANTAGONISTS OF METBOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) AND METHODS OF PREVENTION AND TREATMENT OF GASTROESOPHAGEAL REFLUX (OPTIONS) Russian patent published in 2008 - IPC A61K31/44 A61K31/4439 A61P1/04 A61P11/06 A61P11/04 A61P11/00 

FIELD: medicine; veterinary.

SUBSTANCE: antagonists of metabotropic glutamate receptor 5 (MGLUR5) are suggested to inhibit the transit relaxation of the inferior esophageal sphincter, as well as the corresponding method of treatment and/or prevention of related disorders. Particularly, such disorders include gastroesophageal reflux, gastroesophageal reflux disease, regurgitation, pulmonary disease, hypoplasia of organism, and asthma. The following antagonists of metabotropic glutamate receptor 5 are preferable: 2-methyl-6-(fenyl-etynyl) pyridine, hydrochloride 2- methyl-6-(fenyl-etynyl) pyridine, 3-[3-(5- fluoropyridine -2-il)-1,2,4-oxadiazol-5-il]-5-(metoxymethyl) benzonitrile, 3-fluor-5-[3-(5- fluoropyridine -2-il)-1,2,4- oxadiazol-5-il] benzonitrile.

EFFECT: compounds inhibited the pressure of inferior esophageal sphincter decreased by infusion pomp, in dogs.

26 cl, 4 tbl, 3 ex